Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivotal Therapeutics Inc  

(Public, CNSX:PVO)   Watch this stock  
Find more results for PVO
0.0000 (0.00%)
Jun 26 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.05 - 0.18
Open     -
Vol. 0.00
Mkt cap 7.13M
P/E     -
Div/yield     -
EPS -0.05
Shares 95.01M
Beta     -
Inst. own     -
Jun 1, 2015
Q1 2015 Pivotal Therapeutics Inc Earnings Release
Apr 30, 2015
Full Year 2014 Pivotal Therapeutics Inc Earnings Release

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -776.68% -1755.14%
Operating margin -462.33% -1883.34%
EBITD margin - -1849.58%
Return on average assets -248.75% -256.34%
Return on average equity - -
CDP Score - -


81 Zenway Blvd Unit 10
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)

Website links


Pivotal Therapeutics, Inc. is a Canada-based specialty pharmaceutical company with a focus on cardiovascular disease and overall health. The company’s lead product VASCAZEN is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosaophexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. Its second product, OMAZEN is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health.

Officers and directors

Rachelle MacSweeney President, Director
Eugene G. Bortoluzzi Chief Executive Officer, Chief Financial Officer, Director
George Jackowski Ph.D. Chief Scientific Officer, Director
John S. Gebhardt Non-Executive Chairman of the Board
Age: 66
James J. Carey Independent Director
Giuseppe Simeone Independent Director